KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Charles River Laboratories International (CRL) Shares Outstanding (2016 - 2025)

Charles River Laboratories International has reported Shares Outstanding over the past 17 years, most recently at $49.2 million for Q4 2025.

For Q4 2025, Shares Outstanding fell 3.76% year-over-year to $49.2 million; the TTM value through Dec 2025 reached $49.2 million, down 3.76%, while the annual FY2025 figure was $49.2 million, 3.76% down from the prior year.
Shares Outstanding for Q4 2025 was $49.2 million at Charles River Laboratories International, roughly flat from $49.2 million in the prior quarter.
Over five years, Shares Outstanding peaked at $51.7 million in Q3 2024 and troughed at $49.2 million in Q3 2025.
A 5-year average of $50.9 million and a median of $51.1 million in 2022 define the central range for Shares Outstanding.
Biggest five-year swings in Shares Outstanding: surged 34865.28% in 2021 and later decreased 4.84% in 2025.
Year by year, Shares Outstanding stood at $50.5 million in 2021, then increased by 0.92% to $50.9 million in 2022, then grew by 0.77% to $51.3 million in 2023, then fell by 0.38% to $51.1 million in 2024, then dropped by 3.76% to $49.2 million in 2025.
Business Quant data shows Shares Outstanding for CRL at $49.2 million in Q4 2025, $49.2 million in Q3 2025, and $51.3 million in Q2 2025.